About this file

This is Amendment #2 to RFP 75N95025R00005, posted on 1/14/2025, which provides responses to questions received as of 1/3/2025 regarding drug product development.

The Q&A clarifies several technical requirements, including: 1) The plasmid master cell banks refer to E.coli strains used for preparing cGMP grade plasmids; 2) Stability studies must be performed on both drug product and drug substance for up to 36 months under ICH procedures at specified temperatures; 3) For the Sample Task Order, formulation buffer should be developed for cryogenically stored liquid formulation stable up to 60 months, with lyophilization capability described but not required; 4) The certificate of analysis timeline is extended to 90 days after receiving all test results, accounting for the 28-day In Vitro Adventitious Agent assay. All other terms and conditions remain unchanged.

View the file

Other files

File Type Posted
Amendment 1 12_20_2024.pdf PDF
RFP TRND 3 11_27_24 Final_Clean.pdf PDF
Attachment17-Reps and Certs Section K Form.pdf PDF
Attachment11-FAR_Clause_Deviation_Acknowledgement_mc.pdf PDF
Attachment6 - Sample TO_Area3_4.17.23 Biologics.pdf PDF
Attachment15-Offerors_Points_of_Contact.pdf PDF
Attachment21-Quality_Agreement_template.pdf PDF
Attachment12-Additional_Business_Proposal_Instructions_Template_5.11.2023.pdf PDF
Attachment10-Summary_of_Related_Activities.pdf PDF
Attachment4 - Sample TO_Area1_Small Molecule 4.17.23.pdf PDF
Attachment1-Packaging_and_Delivery_of_Proposals.pdf PDF
Attachment9-Technical_Proposal_Cost_Summary_mc.pdf PDF
Attachment3 - Ramp-On - TRND 3 - SOW - CMC DP 8_23_24.pdf PDF
Attachment24_General Clauses.pdf PDF
Attachment7 Additional Technical Proposal Instructions_Template_5.26.23_FINAL.pdf PDF
Attachment8-Project_Objectives_NIH1688-1_mc.pdf PDF
Attachment22-CMO_Supplier_Audit_Questionnaire.pdf PDF
Attachment19-NIH(RC)1_Supplement.pdf PDF
Attachment18- Invoice_Financing_Request_Instructions-CR-NIHRC-1.pdf PDF
Attachment23-NIH_Supplier_Qualification_Questionnaire_Supplemental_.pdf PDF
Attachment5 - Sample TO_Area2_4.17.23 Peptides.pdf PDF
Attachment25- QA Original RFP.pdf PDF
Attachment14-Breakdown_of_Proposed_Estimated_Costs(plusfee)(5.19.23).xlsx XLSX spreadsheet
Attachment16-Disclosure_of_Lobbying_Activities.pdf PDF
Attachment20-Invoice_FInstructions for NIH Fixed Price Contracts NIH(RC)-2.pdf PDF
Attachment13- Proposal_Summary_and_Data_Record_NIH-2043_Fillable.pdf PDF
Attachment2-Proposal_Intent_Response_Form_FINAL.pdf PDF
Show all 27

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

AMENDMENT #2: RFP 75N95025R00005

The purpose of this Amendment is to:

1) Provide responses to Questions received as of 1/3/2025.

ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED

AMENDMENT 2 – POSTED 1/14/2025

Drug Product: Questions and Answers

1. The Sample Task Order for Technical Area 3, Task 1in Section E, includes the following subtask: Generate and release plasmid master cell banks for the gene of interest plasmid, Rep-Cap and AAV Helper plasmids. Plasmid master cell banks is an unfamiliar term. Does this refer to the master cell bank that will be transfected during cell culture, or is this something different?

A. The pMCB that we are referring here is for the E.coli strains that you use for preparing the cGMP grade plasmids

2. The Sample Task Order for Technical Area 3, Task 1 in Section E, includes the following subtask: Develop and qualify payload-specific analytical methods for product release specifications and stability indication. Is this the same assay as in Task 2 (Bulk Drug Substance, subtask 1)?

A. Yes.

3. The Sample Task Order for Technical Area 3, Task 1 in Section E, includes the following subtask: Perform standard stability studies on the cGMP material up to 36 M under ICH procedures at 2-8°C, negative 20°C and negative 70°C. Does this apply to drug substance and drug product, or just drug product?

A. Both for Drug Product and Drug Substance

4. The Statement of Work indicates formulation studies should include: excipient screening, optimize, and develop final formulation buffer for liquid formulation and lyophilization protocol for lyophilized DP. The Sample Task Order for Technical Area 3 does not mention lyophilization. We interpret this to mean that the proposal budget (based on the sample task order) should be developed for a cryogenically stored liquid formulation, but the proposal should highlight capability to produce a lyophilized product. Is this an accurate interpretation of the intent of the Statement of Work and Sample Task Order?

A. Yes, for the purposes of responding to the Sample Task Order, the formulation buffer should be developed for a cryogenically stored liquid formulation that will keep the drug product stable up to 60 M. Capability to lyophilize drug products is important to describe in the overall RFP response but is not a specific requirement of the Sample Task Order in this case.

5. The Sample Task Order for Technical Area 3, subtask 3 in Section G, requires that the certificate of analysis be provided within 30 calendar days; but Task 2, requires the use of a 28-day In Vitro Adventitious Agent assay. Considering test scheduling, testing, and report generation, is 90 days acceptable?

A. Within 90 days is acceptable. We mean 30 days after you get the results for all the relevant measures (process/quality attributes) on the DS and DP.

File details come from the government source that posted it. Updated .